Posts tagged liver cancer
Maxim vaults BeiGene price target to $120

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced solid tumors at the 20th annual meeting of the Chinese Society of Clinical Oncology in Xiamen, China.

Read More
ContraVir updates action of HBV inhibitor

ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X protein (HBx) and host cyclophilin A, with nanomolar potency. 

Read More
HCW analyst assumes coverage of Celsion

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.

Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.

Read More
Can-Fite CEO to chair cancer conference session

Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver, Canada on Jan. 24-28.

This year’s Purinergic Signaling symposium is a joint session with Keystone Symposia J6 Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies. The conference will focus on the leading developments in purinergic receptors, including the A3 adenosine receptor (A3AR) in the treatment of cancer.

Read More
Can-Fite unveils clinical milestones for 2016

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016.

“We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their efficacy across six major indications,” CEO, Dr. Pnina Fishman, said in a statement.

Read More